Bloomberg
Jack Ma's Ant Group Explores ChatGPT-Style Services. Challenges Baidu with Investment in AI
Uber Rival Bolt Taps AI Robots For Food Delivery
Reuters
YouTube Takes on TikTok in South Korea, Preps Up For Shopping Channel Debut Amid Competition
Cisco Launches Power-Efficient Networking Chips, Takes on Broadcom and Marvell in AI Arena
Chinese Regulators Reprimand Starbucks And Shake Shack Over Privacy Breach
Benzinga
Dollar Tree Targets Achieving $10+ EPS In 2026, Sees Future Cash Flow For Capital Allocation
FDA Approves New Class of Oral Medicines for Children with Type 2 Diabetes
- On Tuesday, the FDA approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) as additions to diet and exercise to improve blood sugar control in children ten years and older with type 2 diabetes.
- These approvals provide a new class of medicines taken by mouth to treat pediatric type 2 diabetes.
- The FDA granted approvals of Jardiance and Synjardy to Boehringer Ingelheim.
Panasonic Energy, Mazda Discuss Battery Supply Partnership
Mastercard's Green Initiative: Introducing a Global Strategy for Payment Card Recycling
RTX Secures $1.15B Contract From US Air Force; Collins Aerospace Inks MRO Agreement With Envoy Air
Piaggio Unveils Vespa's Disney Mickey Mouse Edition: Tribute to Disney's 100th Anniversary
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
